阿奇霉素和乙胺丁醇间歇治疗非空洞性鸟分枝杆菌复合体肺病。
Intermittent Treatment with Azithromycin and Ethambutol for Noncavitary Mycobacterium avium Complex Pulmonary Disease.
机构信息
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
出版信息
Antimicrob Agents Chemother. 2019 Dec 20;64(1). doi: 10.1128/AAC.01787-19.
Abstract
We evaluated the efficacy of intermittent azithromycin and ethambutol therapy for noncavitary complex pulmonary disease (MAC-PD). Twenty-nine (76%) of 38 patients achieved sputum culture conversion after 12 months of treatment, and sputum smear positivity was an independent factor for failure to achieve culture conversion (adjusted odds ratio, 26.7; 95% confidence interval, 2.1 to 339.9; = 0.011). Intermittent azithromycin and ethambutol may be an optional treatment regimen for noncavitary MAC-PD.
摘要
我们评估了间断阿奇霉素和乙胺丁醇疗法治疗非空洞性复杂肺部疾病（MAC-PD）的疗效。38 例患者中，29 例（76%）在治疗 12 个月后痰培养转阴，痰涂片阳性是未达到培养转阴的独立因素（调整优势比，26.7；95%置信区间，2.1 至 339.9；=0.011）。间断阿奇霉素和乙胺丁醇可能是治疗非空洞性 MAC-PD 的一种可选治疗方案。
相似文献
1
Intermittent Treatment with Azithromycin and Ethambutol for Noncavitary Mycobacterium avium Complex Pulmonary Disease.阿奇霉素和乙胺丁醇间歇治疗非空洞性鸟分枝杆菌复合体肺病。
Antimicrob Agents Chemother. 2019 Dec 20;64(1). doi: 10.1128/AAC.01787-19.
2
Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.分枝杆菌属鸟分枝杆菌复合体肺部结节状支气管扩张症的间歇性抗生素治疗。
Am J Respir Crit Care Med. 2015 Jan 1;191(1):96-103. doi: 10.1164/rccm.201408-1545OC.
3
Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease.克拉霉素耐药鸟分枝杆菌复合群肺病的有效治疗方法。
J Infect Chemother. 2020 Jul;26(7):676-680. doi: 10.1016/j.jiac.2020.02.008. Epub 2020 Mar 11.
4
Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.乙胺丁醇和利福平在治疗鸟分枝杆菌复合体肺病中的作用。
BMC Pulm Med. 2019 Nov 11;19(1):212. doi: 10.1186/s12890-019-0982-8.
5
Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance.阿奇霉素和乙胺丁醇联合治疗方案在肺鸟分枝杆菌感染的中空纤维系统模型中失败是由于获得性耐药。
J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i20-i23. doi: 10.1093/jac/dkx303.
6
Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial.氯法齐明作为替代利福平治疗鸟分枝杆菌复合体肺病的安全性和疗效：一项随机试验的结果。
Chest. 2024 May;165(5):1082-1092. doi: 10.1016/j.chest.2023.11.038. Epub 2023 Nov 29.
7
Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.莫西沙星单独及与乙胺丁醇、利福布汀和阿奇霉素联合在体外和体内对鸟分枝杆菌的活性。
Antimicrob Agents Chemother. 2001 Jan;45(1):217-22. doi: 10.1128/AAC.45.1.217-222.2001.
8
Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study.克拉霉素和乙胺丁醇治疗鸟分枝杆菌复合体肺病的疗效。初步研究。
Ann Am Thorac Soc. 2014 Jan;11(1):23-9. doi: 10.1513/AnnalsATS.201308-266OC.
9
Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium.阿奇霉素联合乙胺丁醇与克拉霉素联合乙胺丁醇治疗人类免疫缺陷病毒感染患者鸟分枝杆菌复合菌血症的随机开放标签试验。退伍军人事务部艾滋病毒研究联盟。
Clin Infect Dis. 1998 Nov;27(5):1278-85. doi: 10.1086/514999.
10
Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease.阿奇霉素的血浆峰浓度与鸟分枝杆菌复合群肺病的治疗反应
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6076-83. doi: 10.1128/AAC.00770-16. Print 2016 Oct.
引用本文的文献
1
Current and emerging treatment strategies for complex pulmonary disease: a narrative review.复杂肺部疾病的当前及新出现的治疗策略：一篇叙述性综述
Ewha Med J. 2025 Apr;48(2):e25. doi: 10.12771/emj.2025.00080. Epub 2025 Mar 26.
2
Treatment Outcomes of Complex Pulmonary Disease with a 2-drug Daily Regimen Using Macrolide and Ethambutol.使用大环内酯类药物和乙胺丁醇每日两药方案治疗复杂肺部疾病的疗效
Open Forum Infect Dis. 2025 May 13;12(6):ofaf292. doi: 10.1093/ofid/ofaf292. eCollection 2025 Jun.
3
High-Throughput Sequencing of Nontuberculous Mycobacterial Flora and in Cattle.牛非结核分枝杆菌菌群的高通量测序
Vet Sci. 2025 Mar 14;12(3):275. doi: 10.3390/vetsci12030275.
4
Growing from common ground: nontuberculous mycobacteria and bronchiectasis.从共同基础发展而来：非结核分枝杆菌与支气管扩张症。
Eur Respir Rev. 2024 Jul 3;33(173). doi: 10.1183/16000617.0058-2024. Print 2024 Jul.
5
Rifampicin has no role in treatment of complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint.利福平在治疗复杂肺部疾病中没有作用，需要使用杀菌药物：一个观点。
Eur Respir J. 2024 May 2;63(5). doi: 10.1183/13993003.02210-2023. Print 2024 May.
6
Clofazimine as a substitute for rifampicin improves efficacy of pulmonary disease treatment in the hollow-fiber model.氯法齐明替代利福平可提高中空纤维模型中肺病治疗的疗效。
Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0115723. doi: 10.1128/aac.01157-23. Epub 2024 Jan 23.
7
Mycobacterium Avium Complex Infection of the Spine in a Patient Without Acquired Immune Deficiency Syndrome: A Case Report and Literature Review.患者无获得性免疫缺陷综合征时发生脊柱鸟分枝杆菌复合体感染：病例报告及文献复习。
Orthop Surg. 2023 Jun;15(6):1707-1715. doi: 10.1111/os.13736. Epub 2023 Apr 24.
8
Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use.空洞型鸟分枝杆菌复合体肺病采用链霉素或阿米卡星治疗的效果比较。
Microbiol Spectr. 2023 Jun 15;11(3):e0474122. doi: 10.1128/spectrum.04741-22. Epub 2023 Apr 6.
9
Radiologic Subtypes and Treatment Outcome of Unclassifiable Type Complex Pulmonary Disease.无法分类型复杂肺部疾病的放射学亚型和治疗结果。
J Korean Med Sci. 2023 Jan 16;38(3):e16. doi: 10.3346/jkms.2023.38.e16.
10
Variability of Complex Isolates Drug Susceptibility Testing by Broth Microdilution.采用肉汤微量稀释法对复杂分离株进行药敏试验的变异性
Antibiotics (Basel). 2022 Dec 4;11(12):1756. doi: 10.3390/antibiotics11121756.
本文引用的文献
1
Epidemiology of Nontuberculous Mycobacteriosis.非结核分枝杆菌病的流行病学。
Semin Respir Crit Care Med. 2018 Jun;39(3):325-335. doi: 10.1055/s-0038-1651491. Epub 2018 Aug 2.
2
Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease.大环内酯类耐药与难治性鸟分枝杆菌复合群肺病再感染的发生
Am J Respir Crit Care Med. 2018 Nov 15;198(10):1322-1330. doi: 10.1164/rccm.201802-0321OC.
3
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).英国胸科学会非结核分枝杆菌肺病（NTM-PD）管理指南。
Thorax. 2017 Nov;72(Suppl 2):ii1-ii64. doi: 10.1136/thoraxjnl-2017-210927.
4
Outcomes of complex lung disease based on clinical phenotype.基于临床表型的复杂肺部疾病的结局。
Eur Respir J. 2017 Sep 27;50(3). doi: 10.1183/13993003.02503-2016. Print 2017 Sep.
5
Treatment of Non-Tuberculous Mycobacterial Lung Disease.非结核分枝杆菌肺病的治疗
Curr Treat Options Infect Dis. 2016 Dec;8(4):275-296. doi: 10.1007/s40506-016-0086-4. Epub 2016 Oct 11.
6
Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease.阿奇霉素的血浆峰浓度与鸟分枝杆菌复合群肺病的治疗反应
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6076-83. doi: 10.1128/AAC.00770-16. Print 2016 Oct.
7
Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes.肺部鸟分枝杆菌复合群疾病中克拉霉素和利福平的血清浓度：药物相互作用导致的长期变化及其与临床结局的关联
J Pharm Health Care Sci. 2015 Nov 14;1:32. doi: 10.1186/s40780-015-0029-0. eCollection 2015.
8
Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review.人类非结核分枝杆菌肺部感染的流行病学：综述
Clin Chest Med. 2015 Mar;36(1):13-34. doi: 10.1016/j.ccm.2014.10.002. Epub 2014 Nov 6.
9
Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.分枝杆菌属鸟分枝杆菌复合体肺部结节状支气管扩张症的间歇性抗生素治疗。
Am J Respir Crit Care Med. 2015 Jan 1;191(1):96-103. doi: 10.1164/rccm.201408-1545OC.
10
Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study.克拉霉素和乙胺丁醇治疗鸟分枝杆菌复合体肺病的疗效。初步研究。
Ann Am Thorac Soc. 2014 Jan;11(1):23-9. doi: 10.1513/AnnalsATS.201308-266OC.
Zotero 插件